Phenotypic changes of leukemic cells in a patient with prolympho-plasmacytic leukaemia after treatment with fludarabine.
Loria
M P
MP
Dipartimento di Clinica Medica, Immunologia e Malattie Infettive, Università degli Studi di Bari.
Dell'Osso
A
A
Grande
M
M
Dambra
P
P
D'Oronzio
L
L
Crollo
R
R
Lasaracina
E
E
Lucivero
G
G
D000368:Aged; D015703:Antigens, CD / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D016130:Immunophenotyping; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007952:Leukemia, Plasma Cell / Q000276:immunology* / Q000473:pathology*; D015463:Leukemia, Prolymphocytic / Q000276:immunology* / Q000473:pathology*; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D010641:Phenotype; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D015703:Antigens, CD; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D014740:Vidarabine; C024352:fludarabine